Abbreviated Name

Lung Ref Set A App: Takacs (2010)

Lead Investigator

Takacs, Laszlo — Biosystems International SAS

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Srivastava, Sudhir — National Cancer Institute
• Takacs, Laszlo — Biosystems International SAS
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

No abstract availalbe.

Aims

Validate the panel of monoclonal antibodies

Analytic Method

To complete the research phase of the project, we refine our algorithm. From this experiment, we will select the final panel of antibodies which will be used to develop the final diagnostic test. This final panel of antibodies used is selected as the panel showing the highest discrimination between the two groups (control vs. lung cancer). A learning algorithm based on LDA (Linear Discrimination Analysis) model is applied on each potential panel (called classifiers) and the performance of each classifier is evaluated calculating the AUC (area under the receiver operating curve) by Leave-One-Out-Cross validation (LOOCV). With the refined algorithm, we would like to test the Combined Pre-Validation Set A of the NCI lung cancer reference set.

Comments

No comments available.

Outcome

4 monoclonal antibody markers and a combination panel (BSI) were evaluated on the EDRN Lung reference Set A. Discrimination between (a) cases of lung cancer and high-risk controls and between b) cases of lung cancer and non-cancers (high-risk controls plus other cancers) were evaluated. AUCs demonstrated were (a) between 0.58 and 0.64 for individual markers and 0.65 (95% CI 0.6,0.7) for BSI (N case = 219, N control = 186); (b) between 0.6 and 0.67 for individual markers and 0.67 (95% CI 0.62,0.72) for BSI (N case = 219, N control = 210). Two BSI-based rules demonstrated (a) (sens,spec)=(38.36%,82.8%) and (sens,spec)=(50.23%,68.89%); (b) (sens,spec)=(38.36%,83.81%) and (sens,spec)=(50.23%,75.1%).

Secure Outcome

No secure outcome available.

Publications

• No publications available at this time for this protocol.

Biomarkers

• BSI panel (mAb)
• SW1 (mAb)
• SW2 (mAb)
• SW3 (mAb)
• SW4 (mAb)

Data Collections

• No data collections available at this time for this protocol.

 Team Project

Start Date

Aug 24 2010

Estimated Finish Date

Dec 24 2010

Finish Date

Feb 27 2012

Protocol ID

321

Protocol Type

Reference Set

Fields of Research

• Proteomics

Collaborative Group

Lung and Upper Aerodigestive Cancers Research Group

Cancer Types

• Malignant neoplasm of bronchus and lung

Phased Status

1